The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,404.00
Bid: 12,416.00
Ask: 12,418.00
Change: 44.00 (0.36%)
Spread: 2.00 (0.016%)
Open: 12,330.00
High: 12,450.00
Low: 12,316.00
Prev. Close: 12,360.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-EU expects to vaccinate majority by end-June - Bloomberg

Tue, 06th Apr 2021 10:33

(Adds details)

April 6 (Reuters) - Most European Union states will have
enough COVID-19 vaccines to immunize the majority of their
people by the end of June, Bloomberg News reported on Tuesday,
citing an internal memo.

Germany, France, Italy, Spain and the Netherlands will be in
a position to fully inoculate more than 55% of their populations
by June end, the report https://www.bloomberg.com/news/articles/2021-04-06/eu-will-near-virus-immunity-by-end-june-internal-memo-shows?sref=SCAzRb9t
added, citing projections in the memo by the EU executive, the
European Commission.

The numbers confirm public estimates of vaccines the
27-nation bloc expects to receive in the second quarter.

The Commission has repeatedly said the EU, with a population
of nearly 450 million, is to receive about 360 million doses by
the end of June in addition to about 100 million already
shipped.

That would be sufficient to meet its target of vaccinating
at least 70% of the bloc's adult population by the summer.

The bloc expects to receive in the April-June period 55
million doses of the single-dose vaccine developed by Johnson &
Johnson, and another 300 million of two-dose shots from
BioNTech-Pfizer , AstraZeneca and
Moderna.

It is however unclear whether all expected doses will be
delivered in line with timetables. The EU received about half of
the expected doses in the first quarter because AstraZeneca made
major cuts in its supplies to the EU then.

The new estimates already factor in a further major cut in
AstraZeneca supplies in the second quarter.

The EU has coordinated the purchase of vaccines with EU
governments but has no power on vaccination plans, which are run
by EU states.

Roll-outs depend on supplies but also on vaccination
programmes, which have often been hampered in EU states because
of safety and effectiveness concerns over the AstraZeneca
vaccine.

The vaccine roll-out picked up in the bloc at the end of
March after a slow start.
(Reporting by Aakriti Bhalla in Bengaluru; additional reporting
by Francesco Guarascio in Brussels; Editing by Andrew Cawthorne
and Giles Elgood)

More News
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.